Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

BACKGROUND: In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilhelm, Alexander, Widera, Marek, Grikscheit, Katharina, Toptan, Tuna, Schenk, Barbara, Pallas, Christiane, Metzler, Melinda, Kohmer, Niko, Hoehl, Sebastian, Marschalek, Rolf, Herrmann, Eva, Helfritz, Fabian A., Wolf, Timo, Goetsch, Udo, Ciesek, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271884/
https://www.ncbi.nlm.nih.gov/pubmed/35834885
http://dx.doi.org/10.1016/j.ebiom.2022.104158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271884/
https://www.ncbi.nlm.nih.gov/pubmed/35834885
http://dx.doi.org/10.1016/j.ebiom.2022.104158

Ejemplares similares